Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Receives Average Rating of “Moderate Buy” from Brokerages

Posted by Stanley Muller on Jun 12th, 2026

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA – Get Free Report) has been given an average recommendation of “Moderate Buy” by the eleven research firms that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $42.4286.

Several analysts have weighed in on the stock. Guggenheim reissued a “buy” rating and issued a $40.00 price target (up from $36.00) on shares of Damora Therapeutics, Inc. Common Stock in a research note on Tuesday, February 17th. HC Wainwright started coverage on Damora Therapeutics, Inc. Common Stock in a report on Thursday. They issued a “buy” rating and a $45.00 price objective on the stock. UBS Group initiated coverage on Damora Therapeutics, Inc. Common Stock in a research report on Tuesday, February 17th. They issued a “buy” rating and a $45.00 price objective for the company. Evercore began coverage on Damora Therapeutics, Inc. Common Stock in a research note on Wednesday, March 25th. They set an “outperform” rating and a $46.00 price objective for the company. Finally, TD Cowen assumed coverage on shares of Damora Therapeutics, Inc. Common Stock in a report on Monday. They issued a “buy” rating on the stock.

View Our Latest Research Report on Damora Therapeutics, Inc. Common Stock

Institutional Investors Weigh In On Damora Therapeutics, Inc. Common Stock

Large investors have recently added to or reduced their stakes in the company. Janus Henderson Group PLC purchased a new position in shares of Damora Therapeutics, Inc. Common Stock in the fourth quarter valued at about $40,000. Geode Capital Management LLC bought a new position in shares of Damora Therapeutics, Inc. Common Stock during the fourth quarter valued at about $266,000. Virtu Financial LLC purchased a new stake in shares of Damora Therapeutics, Inc. Common Stock during the third quarter worth about $49,000. Sigma Planning Corp bought a new stake in shares of Damora Therapeutics, Inc. Common Stock in the fourth quarter worth about $334,000. Finally, Two Sigma Investments LP bought a new stake in shares of Damora Therapeutics, Inc. Common Stock in the third quarter worth about $76,000. Institutional investors own 14.20% of the company’s stock.

Damora Therapeutics, Inc. Common Stock Price Performance

NASDAQ:DMRA opened at $21.36 on Friday. The company has a market capitalization of $1.31 billion, a price-to-earnings ratio of -3.83 and a beta of 1.46. The business has a 50 day moving average of $24.59 and a 200 day moving average of $25.37. Damora Therapeutics, Inc. Common Stock has a 1-year low of $2.45 and a 1-year high of $38.33.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA – Get Free Report) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.23). As a group, sell-side analysts anticipate that Damora Therapeutics, Inc. Common Stock will post -2.13 EPS for the current year.

About Damora Therapeutics, Inc. Common Stock

(Get Free Report)

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.